NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $4.22 +0.01 (+0.24%) Closing price 04:00 PM EasternExtended Trading$4.24 +0.02 (+0.36%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.15▼$4.2650-Day Range$4.19▼$5.0252-Week Range$3.81▼$5.55Volume485,040 shsAverage Volume570,511 shsMarket Capitalization$249.36 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingStrong Buy Company Overview Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreVNDA MarketRank™: Vanda Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 252nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.36% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 2,603.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.77 Percentage of Shares Shorted8.36% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 2,603.18%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.04 News SentimentVanda Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows18 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,700% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have bought 299.63% more of their company's stock than they have sold. Specifically, they have bought $128,400.00 in company stock and sold $32,130.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Large Increase in Short InterestAugust 3 at 2:58 AM | americanbankingnews.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 6 at 2:00 AM | Priority Gold (Ad)Vanda (VNDA) Q2 Revenue Rises 4%August 1, 2025 | fool.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 1, 2025 | finanznachrichten.deVanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comVanda Pharmaceuticals Q2 2025 Earnings: EPS Misses at -$0.46, Revenue Falls Short at $52.6 MillionJuly 31, 2025 | gurufocus.comVanda Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY25 outlookJuly 31, 2025 | seekingalpha.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $4.79 on January 1st, 2025. Since then, VNDA shares have decreased by 11.9% and is now trading at $4.22. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Thursday, July, 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.12. The biopharmaceutical company had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 12.89% and a negative net margin of 32.90%. Read the conference call transcript. Who are Vanda Pharmaceuticals' major shareholders? Top institutional shareholders of Vanda Pharmaceuticals include Public Employees Retirement System of Ohio (0.06%), R Squared Ltd (0.03%) and CWM LLC (0.02%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2025Today8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$16.50 High Price Target$20.00 Low Price Target$13.00 Potential Upside/Downside+291.0%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.90 million Net Margins-32.90% Pretax Margin-41.77% Return on Equity-12.89% Return on Assets-10.47% Debt Debt-to-Equity RatioN/A Current Ratio3.25 Quick Ratio3.23 Sales & Book Value Annual Sales$198.77 million Price / Sales1.25 Cash FlowN/A Price / Cash FlowN/A Book Value$8.23 per share Price / Book0.51Miscellaneous Outstanding Shares59,090,000Free Float53,180,000Market Cap$249.36 million OptionableOptionable Beta0.72 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VNDA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredInstant Cash (every 3rd Monday)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.